Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State
Open Access
- 1 May 2016
- journal article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 172, 127-135
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- The long quest for neonatal screening for severe combined immunodeficiencyJournal of Allergy and Clinical Immunology, 2012
- The case for newborn screening for severe combined immunodeficiency and related disordersAnnals of the New York Academy of Sciences, 2011
- A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID)Molecular Genetics and Metabolism, 2011
- Early vs. delayed diagnosis of severe combined immunodeficiency: A family perspective surveyClinical Immunology, 2011
- Why Newborn Screening for Severe Combined Immunodeficiency Is Essential: A Case ReportPediatrics, 2010
- Guidelines for implementation of population‐based newborn screening for severe combined immunodeficiencyJournal of Inherited Metabolic Disease, 2010
- Systematic Evidence Review of Newborn Screening and Treatment of Severe Combined ImmunodeficiencyPediatrics, 2010
- Projected Costs, Risks, and Benefits of Expanded Newborn Screening for MCADDPediatrics, 2010
- Potential Costs and Benefits of Newborn Screening for Severe Combined ImmunodeficiencyThe Journal of Pediatrics, 2005
- Early diagnosis of severe combined immunodeficiency syndrome.Archives of Disease in Childhood, 1994